Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
07/20 AMGEN : FDA Accepts Biologics License Application For Aimovig™ (erenumab)
07/20 AMGEN : Data on DNA Research Reported by Researchers at Amgen (Rhodium metalloin..
07/20 AMGEN : Announces Webcast of 2017 Second Quarter Financial Results
07/20 AMGEN : Learn More About The Shape of Drugs to Come and Amgen’s Modality T..
07/20 AMGEN : And QB3@953 Announce Winners Of The Amgen Golden Ticket
07/20 AMGEN : And Allergan To Discuss Data Supporting Biologics License Application Fo..
07/20 AMGEN : Study Results from Amgen Update Understanding of Chemical Biology (Progr..
07/20 AMGEN : Second Phase 3 Study Shows KYPROLIS® Carfilzomib Regimen Significantly I..
07/20 AMGEN : Findings from Amgen Yields New Data on Bone and Joint Research (Kinetic ..
07/18 FDA REJECTS AMGEN, INC. (NASDAQ : AMGN) Osteoporosis Drug, Requests More Data
More news
News from SeekingAlpha
07/20 FDA accepts Amgen's marketing application for migraine biologic erenumab, act..
07/20 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 20, 2017
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/19 Immunogen Finally Moving 'FORWARD'?
07/19 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 19, 2017
Financials ($)
Sales 2017 22 677 M
EBIT 2017 11 751 M
Net income 2017 8 113 M
Debt 2017 3 525 M
Yield 2017 2,53%
P/E ratio 2017 16,19
P/E ratio 2018 16,03
EV / Sales 2017 5,97x
EV / Sales 2018 5,45x
Capitalization 131 769 M
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 182 $
Spread / Average Target 1,8%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline Executive VP, Chief Financial & Accounting Officer
Sean E. Harper Executive Vice President-Research & Development
Paul R. Eisenberg Chief Medical Officer & Senior VP-Global Medical
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN22.55%131 769
CELGENE CORPORATION16.63%105 411
GILEAD SCIENCES1.55%95 025
REGENERON PHARMACEUTICALS35.56%53 867
VERTEX PHARMACEUTICALS116.76%39 774
ACTELION20.86%30 319